DR. ASHRAF A.H.F. EL-SHALAKANY, M.D.

Plain English
This study focused on improving the involvement of patients, caregivers, and the public in the process of clinical trials. The Cairo Consensus Group, made up of 40 experts from 14 countries, created a set of guidelines with 39 recommendations to encourage this involvement and ensure that trials are more trustworthy. The goal is to enhance clinical research by making sure that the voices of those affected by the research are included. Who this helps: This benefits patients and their families, as well as researchers and healthcare organizations.

Plain English
This study looked at the challenges faced by a research ethics committee in Egypt when reviewing 98 COVID-19 research proposals between April and October 2020. The committee had to adapt to a rapid increase in submissions while ensuring ethical standards were met, dealing with issues like informed consent and balancing risks and benefits. Understanding these challenges is important because it highlights the need for effective ethical oversight in urgent research situations like a pandemic. Who this helps: This helps researchers and ethics committees in managing and approving COVID-19 studies effectively.

Plain English
This study looked at how the ratio of endometrial volume to uterine volume (EV/UCV) can help predict whether postmenopausal women with bleeding have cancer. Researchers examined 160 women and found that a ratio greater than 0.017 indicated a higher likelihood of malignancy; specifically, 27 women were diagnosed with endometrial cancer, while 53 had atypical cells, and 80 had benign conditions. This finding is important because it provides a more accurate way to identify women at risk for cancer compared to traditional methods. Who this helps: This helps doctors better assess the risk of cancer in women experiencing postmenopausal bleeding.

Plain English
This study examined the levels of a substance called inhibin in the blood of women with ovarian tumors to see if it could help determine whether those tumors were cancerous. In 50 women with ovarian tumors, the average inhibin level was 1.9 U/mL in those with malignant tumors compared to 0.91 U/mL in benign cases; the test showed a 67.7% success rate in correctly identifying cancerous tumors. This information is important because it helps doctors better predict cancer, which can improve how they guide treatment and manage care for patients. Who this helps: Patients with ovarian tumors and their doctors.

Plain English
This study looked at a method called direct visual inspection (DVI) of the cervix to find early signs of abnormal cells that could lead to cancer. Over 2,000 women participated, and the results showed that DVI was able to detect 71 out of 83 cases of pre-cancerous lesions, which is a sensitivity rate of 85.5%, while traditional cervical smears only identified 14 of those cases. This matters because DVI is an effective screening tool that could be especially useful in places where there aren't enough resources for more complicated tests. Who this helps: This helps women by improving early detection of cervical abnormalities.

Plain English
This study looked at how well specific criteria can predict whether a treatment will successfully stop a dangerous heart rhythm problem called ventricular tachycardia (VT) in patients with coronary artery disease. Researchers tested 20 different VT cases in 15 patients, finding that when all three criteria were met, the treatment worked 100% of the time (19 out of 19 sites). In contrast, the treatment failed 96% of the time (24 out of 25 sites) when the criteria weren’t met. This matters because it helps doctors know when they can effectively use a treatment that targets the heart's electrical signals, potentially leading to better outcomes for patients. Who this helps: Patients with coronary artery disease and recurrent ventricular tachycardia.

Plain English
This study looked at the automatic implantable cardioverter-defibrillator (AICD), a device that helps patients experiencing dangerous heart rhythm problems. Researchers followed 21 patients for an average of 19 months and found that while there were two deaths and some complications requiring further surgery, the device generally helped improve survival rates for patients with severe heart issues. This matters because it shows that the AICD can be an important tool for treating life-threatening heart conditions. Who this helps: This helps patients with serious heart rhythm problems.